The first FDA-approved therapeutic cancer vaccine is sipuleucel-T for prostate cancer, which consists of the prostatic acid phosphatase antigen fused to granulocyte-macrophage colony-stimulating factor (GM-CSF), loaded onto autologous peripheral blood mononuclear cells [26]. The gene discussed is CSF2; the disease is prostate carcinoma.